



LEARN. CONNECT. MAKE WAVES.

# AUTM

## ANNUAL MEETING

Nov 6<sup>th</sup> 2020 ~~2020~~ X OCT 8-11, 2020 SAN DIEGO

### Takeda Strategic Academic Alliances

*Cathy Tralau-Stewart PhD FRSC  
Senior Director Alliances  
Center for External Innovation  
Takeda*




**autm**  
#AUTM2020


## A Diverse and Dynamic Pipeline<sup>1</sup>



**200+**  
ACTIVE PARTNERSHIPS



**40**  
NEW MOLECULAR  
ENTITY CLINICAL  
STAGE ASSETS<sup>2</sup>



PIPELINE WITH  
ORPHAN DRUG  
DESIGNATION

## Expanding Critical Capabilities



CELL THERAPY




GENE THERAPY



DATA SCIENCES

Combining the best of academic and industry research to identify bold projects with potential for breakthrough therapies and to accelerate development



9 Alliances  
19 Institutes  
Pan-TA  
Cross-Modality

# TAKEDA AREAS OF INTEREST



ONCOLOGY	GASTROENTEROLOGY	NEUROSCIENCE	RARE DISEASES
<b>Immuno-Oncology</b> (IFN & novel checkpoints Cell engagers and cell therapies)	Motility disorders	Proteinopathy	Rare hematology
<b>Heme Oncology</b> (multiple myeloma, amyloidosis, myelodysplastic syndrome, acute myeloid leukemia, chronic myeloid leukemia)	Inflammation (IBD)	Nervous system protection/repair (incl. remyelination)	Inborn metabolic disorders
<b>Lung - Non-small cell tumors</b>	Liver disorders	BBB shuttle/delivery to the brain	Neuromuscular
<b>Cold to Hot</b>	Microbiome	Synergistic Pharmacology	Genetic linked diseases
<b>Delivery approaches</b>	Genetic linked diseases	Genetic linked diseases (incl. developmental disorders)	
<b>Novel approaches</b>		Emerging diseases of interest (eg neuro- muscular)	

**Novel approaches**

- Modality agnostic
- Including
  - Gene therapy & technologies
  - Cell therapy
  - Antibodies
  - Oligonucleotides
  - Small molecules
- Gene editing
- Delivery technologies
- Translational medicine

**Plus :**  
**Anything really  
exciting & novel  
(‘high risk’)**

## ONE – PROJECT TEAM COLLABORATIVE RELATIONSHIP BUILDING



- Takeda's aim is to build relationships which enable the **combination of academic and industrial skills and knowledge** to accelerate the development of life changing therapeutics to patients
- Flexible use of in-kind in-house, CRO and funding-based **resources** to accelerate the project plan
- Regular (~bi-weekly) in-person and webex meetings
- Direct support of academic research to deliver pre-clinical and clinical Proof of Concept studies
- Flexible agreements ranging from SRAs to broad alliance and consortium agreements recognizing each partner's skills and needs
- Support for a range of exits including licenses, incubation & start-up creation